How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis

Detalhes bibliográficos
Autor(a) principal: Pinto, Daniel
Data de Publicação: 2020
Outros Autores: Cirnes, Luís, Regina Pinto, Pinto, Pina, Maria João, Troncone, Giancarlo, Schmitt, Fernando
Tipo de documento: Outros
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/106131
Resumo: Introduction: The Portuguese healthcare system had to adapt at short notice to the COVID-19 pandemic. We implemented workflow changes to our molecular pathology laboratory, a national reference center, to maximize safety and productivity. We assess the impact this situation had on our caseload and what conclusions can be drawn about the wider impact of the pandemic in oncological therapy in Portugal. Material and Methods. We reviewed our database for all oncological molecular tests requested between March and April of 2019 and 2020. For each case, we recorded age, sex, region of the country, requesting institution, sample type, testing method, and turnaround time (TAT). A comparison between years was made. Results: The total number of tests decreased from 421 in 2019 to 319 in 2020 (p = 0.0027). The greatest reduction was in clinical trial-related cases. Routine cases were similar between years (267 vs. 256). TAT was higher in 2019 (mean 15 days vs. 12.3 days; p = 0.0003). Medium- to large-sized public hospitals in the north of the country were mostly responsible for the reduction in cases (p = 0.0153). Conclusions: Case reduction was observed at hospitals that have mostly been involved in the treatment of COVID-19 and in the north of the country, the region worst-hit by the pandemic. Similar to other studies, our TAT decreased, even with a similar number of routine cases. Thus, we conclude that it is possible to successfully adapt the workflow of a molecular pathology laboratory to new safety standards without losing efficiency.
id RCAP_67f06608bcfaf1a98d7236fa06e4fc5b
oai_identifier_str oai:run.unl.pt:10362/106131
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling How the COVID-19 Pandemic Impacted Oncological Molecular DiagnosisA Picture from a National Reference Center for Molecular PathologyBiochemistry, Genetics and Molecular Biology(all)Immunology and Microbiology(all)Introduction: The Portuguese healthcare system had to adapt at short notice to the COVID-19 pandemic. We implemented workflow changes to our molecular pathology laboratory, a national reference center, to maximize safety and productivity. We assess the impact this situation had on our caseload and what conclusions can be drawn about the wider impact of the pandemic in oncological therapy in Portugal. Material and Methods. We reviewed our database for all oncological molecular tests requested between March and April of 2019 and 2020. For each case, we recorded age, sex, region of the country, requesting institution, sample type, testing method, and turnaround time (TAT). A comparison between years was made. Results: The total number of tests decreased from 421 in 2019 to 319 in 2020 (p = 0.0027). The greatest reduction was in clinical trial-related cases. Routine cases were similar between years (267 vs. 256). TAT was higher in 2019 (mean 15 days vs. 12.3 days; p = 0.0003). Medium- to large-sized public hospitals in the north of the country were mostly responsible for the reduction in cases (p = 0.0153). Conclusions: Case reduction was observed at hospitals that have mostly been involved in the treatment of COVID-19 and in the north of the country, the region worst-hit by the pandemic. Similar to other studies, our TAT decreased, even with a similar number of routine cases. Thus, we conclude that it is possible to successfully adapt the workflow of a molecular pathology laboratory to new safety standards without losing efficiency.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNPinto, DanielCirnes, LuísRegina Pinto, PintoPina, Maria JoãoTroncone, GiancarloSchmitt, Fernando2020-10-23T23:15:07Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/other1application/pdfhttp://hdl.handle.net/10362/106131eng2314-6133PURE: 26051658https://doi.org/10.1155/2020/8397053info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T17:48:22Zoai:run.unl.pt:10362/106131Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T17:48:22Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis
A Picture from a National Reference Center for Molecular Pathology
title How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis
spellingShingle How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis
Pinto, Daniel
Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)
title_short How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis
title_full How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis
title_fullStr How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis
title_full_unstemmed How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis
title_sort How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis
author Pinto, Daniel
author_facet Pinto, Daniel
Cirnes, Luís
Regina Pinto, Pinto
Pina, Maria João
Troncone, Giancarlo
Schmitt, Fernando
author_role author
author2 Cirnes, Luís
Regina Pinto, Pinto
Pina, Maria João
Troncone, Giancarlo
Schmitt, Fernando
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Pinto, Daniel
Cirnes, Luís
Regina Pinto, Pinto
Pina, Maria João
Troncone, Giancarlo
Schmitt, Fernando
dc.subject.por.fl_str_mv Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)
topic Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)
description Introduction: The Portuguese healthcare system had to adapt at short notice to the COVID-19 pandemic. We implemented workflow changes to our molecular pathology laboratory, a national reference center, to maximize safety and productivity. We assess the impact this situation had on our caseload and what conclusions can be drawn about the wider impact of the pandemic in oncological therapy in Portugal. Material and Methods. We reviewed our database for all oncological molecular tests requested between March and April of 2019 and 2020. For each case, we recorded age, sex, region of the country, requesting institution, sample type, testing method, and turnaround time (TAT). A comparison between years was made. Results: The total number of tests decreased from 421 in 2019 to 319 in 2020 (p = 0.0027). The greatest reduction was in clinical trial-related cases. Routine cases were similar between years (267 vs. 256). TAT was higher in 2019 (mean 15 days vs. 12.3 days; p = 0.0003). Medium- to large-sized public hospitals in the north of the country were mostly responsible for the reduction in cases (p = 0.0153). Conclusions: Case reduction was observed at hospitals that have mostly been involved in the treatment of COVID-19 and in the north of the country, the region worst-hit by the pandemic. Similar to other studies, our TAT decreased, even with a similar number of routine cases. Thus, we conclude that it is possible to successfully adapt the workflow of a molecular pathology laboratory to new safety standards without losing efficiency.
publishDate 2020
dc.date.none.fl_str_mv 2020-10-23T23:15:07Z
2020
2020-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/other
format other
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/106131
url http://hdl.handle.net/10362/106131
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2314-6133
PURE: 26051658
https://doi.org/10.1155/2020/8397053
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545764273913856